Healthcare Industry News: chest tube
News Release - November 9, 2007
Covidien Introduces PleuraSeal(TM) Lung Sealant System to European MarketplaceNew Advanced Hydrogel Technology Provides Effective Sealing of Air Leaks in Thoracic Procedures
NORTH HAVEN, Conn.--(HSMN NewsFeed)--Covidien Ltd. (NYSE: COV, BSX: COV), a leading global provider of healthcare products, has introduced the PleuraSeal™ Lung Sealant System to the European market. The PleuraSeal™ Lung Sealant System, CE Mark approved, is intended for use as a surgical sealant during elective pulmonary resection as an adjunct for standard closure techniques of visceral pleural air leaks.
The PleuraSeal™ Lung Sealant System offers surgeons a unique advanced hydrogel technology that provides an immediate airtight seal that is effective intra-operatively and throughout the critical lung healing period. It may improve patient outcomes by enabling earlier chest tube removal once drainage is complete and by reducing the incidence of prolonged air leaks.
“Our investment and efforts to develop and commercialize new biosynthetic technologies aim to address unmet clinical needs and to improve patient outcomes,” said Scott Flora, President, Surgical Devices, Covidien. “We believe that this highly innovative synthetic sealant will be adopted quickly by any surgeon unsatisfied with the options available today,” added Flora.
During thoracic procedures, air leaks are a common complication that require chest tube management until they resolve, directly impacting patient length of stay. Air leak duration is difficult to predict and, in some cases, may lead to prolonged air leaks and additional complications, including infection.
Dr. Paul De Leyn, Professor of Thoracic Surgery at the University Hospitals Leuven Gasthuisberg in Belgium and Study Coordinating Investigator of the PleuraSeal™ Multi-Center Randomized Post Market Study, stated, “An easy-to-use and effective thoracic lung sealant to address complications in thoracic procedures will be very welcomed by the surgical community. We have been impressed by the performance characteristics of PleuraSeal™ and are pleased to be associated with the clinical study.”
The PleuraSeal™ Lung Sealant System is now available throughout Europe and in select Middle East markets. It has not been approved for use in the United States at this time.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines, including Surgical Devices, Energy-based Devices, Respiratory and Monitoring Solutions, Patient Care and Safety Products, Imaging Solutions, Pharmaceutical Products, Medical Supplies and Retail Products. With 2006 revenue of nearly $10 billion, Covidien has more than 43,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.